SCHEMBL5171

SCHEMBL5171

C[CH]C1(C)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5240 0.85
SCHEMBL5480 0.85
SCHEMBL5275 0.82
SCHEMBL21114244 0.82
SCHEMBL21114246 0.82
SCHEMBL5142 0.82
SCHEMBL21114314 0.82
SCHEMBL21114337 0.82
SCHEMBL4324 0.82
SCHEMBL11857104 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220220102-A1 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2022-07-14 US claimed
EP-3953350-A1 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF The United States of America, as Represented by The Department of Health and Human Services (US) 2022-02-16 EP claimed
WO-2020210785-A1 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2020-10-15 WO claimed
US-20090306442-A1 OLIGOMERISATION CATALYST WITH PENDANT DONOR GROUPS SASOL TECHNOLOGY (PTY) LIMITED (ZA) 2009-12-10 US claimed
CN-101500967-A Oligomerisation catalyst with pendant donor groups SASOL TECH PTY LTD (ZA) 2009-08-05 CN claimed
EP-2024305-A2 OLIGOMERISATION CATALYST WITH PENDANT DONOR GROUPS Sasol Technology (Pty) Ltd (ZA) 2009-02-18 EP claimed
WO-2007138545-A2 OLIGOMERISATION CATALYST WITH PENDANT DONOR GROUPS SASOL TECHNOLOGY (PTY) LIMITED (ZA) 2007-12-06 WO claimed
US-4754059-A ANTISECRETORY AGENT WITH REDUCED DIARRHEA SIDE EFFECT G. D. SEARLE & CO. (US) 1988-06-28 US claimed
US-11981670-B2 Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof DYNAVAX TECHNOLOGIES CORPORATION (US) 2024-05-14 US disclosed
US-11840528-B2 Isoxazolyl ether derivatives as GABAA α5 PAM HOFFMANN-LA ROCHE INC. (US) 2023-12-12 US disclosed
EP-4257198-A2 ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE DERIVATIVES AS TLR7/8 AGONISTS AND USES THEREOF Dynavax Technologies Corporation (US) 2023-10-11 EP disclosed
EP-3672969-B1 ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE DERIVATIVES AS TLR7/8 AGONISTS AND USES THEREOF DYNAVAX TECH CORP (US) 2023-07-05 EP disclosed
WO-2022187206-A1 DUAL-TARGET MU OPIOID AND DOPAMINE D3 RECEPTORS LIGANDS; PREPARATION AND USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2022-09-09 WO disclosed
US-20220220102-A1 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2022-07-14 US disclosed
EP-1213281-B1 NOVEL AMIDE DERIVATIVES BANYU PHARMA CO LTD (JP) 2004-02-18 EP disclosed
WO-2003049542-A1 PYRAZOLES-PYRIMIDINE FUNGICIDES SYNGENTA PARTICIPATIONS AG (CH) 2003-06-19 WO disclosed
WO-2003029249-A1 THIAZOLYL SUBSTITUTED AMINOPYRIMIDINES AS PLANT PROTECTION AGENTS SYNGENTA PARTICIPATIONS AG (CH) 2003-04-10 WO disclosed
US-20030055021-A1 Compounds for the treatment of ischemia PFIZER, INC. 2003-03-20 US disclosed
EP-1241176-A1 Purine derivatives for the treatment of ischemia Pfizer Products Inc. (US) 2002-09-18 EP disclosed
EP-1213281-A1 NOVEL AMIDE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-06-12 EP disclosed